To the Editor: Dr Shirani and colleagues1 suggested that interferon beta treatment was not associated with a reduction in progression of long-term disability in patients with multiple sclerosis (MS). In contrast, long-term follow-up of a randomized controlled trial of interferon beta-1b reported a 60% to 70% reduction in long-term disability2 and a 46% to 47% reduction in mortality.3 Although Shirani et al1 did not cite these studies, both reports used bias-reduction methods. Time zero was the same for all patients (either eligibility for interferon beta treatment or trial entry) so that there was no immortal time bias,4 and both analyses used propensity score (covariate) adjustment.5
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.